UPDATE: Deutsche Bank Initiates Coverage on Gen-Probe at Buy
According to Deutsche Bank, Gen-Probe (NASDAQ: GPRO) coverage is initiated at Buy.
Deutsche Bank said that GPRO is a leading player in the $4.5+ Bn MDx market, with a premier women's health and blood screening franchise. “Given our expectations for new product momentum to drive low double digit rev growth in the MT, we rate GPRO shares a Buy with a $70.50 PT.”
Gen-Probe closed yesterday at $56.30.
© 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.